Ibuprofen and/or paracetamol (acetaminophen) for pain relief after surgical removal of lower wisdom teeth, a Cochrane systematic review

E. Bailey,*1 H. Worthington1 and P. Coulthard1

VERIFIABLE CPD PAPER

IN BRIEF

- Provides a summary of the best current evidence on the efficacy of paracetamol and ibuprofen using the third molar pain model.
- Compares the analgesic capabilities of the two agents.
- Considers the evidence for using a single drug that contains both active analgesics.
- Précises the findings from this review in light of other Cochrane reviews in the field.

This paper compares the beneficial and harmful effects of paracetamol, ibuprofen and the novel combination of both in a single tablet for pain relief following the surgical removal of lower wisdom teeth. In this systematic review only randomised controlled double-blinded clinical trials were included. We calculated the proportion of patients with at least 50% pain relief at 2 and 6 hours post dosing, along with the proportion of participants using rescue medication at 6 and 8 hours. Adverse events were also analysed. Data was meta-analysed where possible. Seven studies were included with a total of 2,241 participants enrolled. Ibuprofen 400 mg is superior to 1,000 mg paracetamol with a risk ratio for at least 50% pain relief at 6 hours of 1.47 (95% confidence interval [CI] 1.28 to 1.69). For the combined drug, the risk ratio for at least some maximum pain relief over 6 hours is 1.77 (95% CI 1.32 to 2.39) based on total pain relief (TOTPAR) data. There is high quality evidence that ibuprofen is superior to paracetamol. The novel combination drug shows encouraging results when compared to the single drugs (based on two trials).

INTRODUCTION

This article is based on the Cochrane review *Ibuprofen and/or paracetamol* (acetaminophen) for pain relief after surgical removal of lower wisdom teeth¹ published in the Cochrane Database of Systematic Reviews (CDSR) 2013. Cochrane reviews are regularly updated as new evidence emerges and in response to feedback, and the CDSR should be consulted for the most recent version of the review.

BACKGROUND

The removal of wisdom teeth is an extremely common surgical procedure with hospital episode statistics estimating that 77,000 patients underwent such a procedure during the year 2009/10.² Research suggests that wisdom tooth removal has an immediate negative impact on patients' working and social lives: in one study patients took an average of 1.6 days off work, with over one third of patients stating that the surgery

¹University of Manchester, School of Dentistry, Higher Cambridge Street, Manchester, M13 9PL *Correspondence to: Mr Edmund Bailey Email: Edmund.bailey@manchester.ac.uk

Refereed Paper Accepted 18 February 2014 DOI: 10.1038/sj.bdj.2014.330 ®British Dental Journal 2014; 216: 451–455 had affected their performance at work.³ Participation in social activities, sports and other hobbies is also negatively affected.⁴ For many patients quality of life (QoL) is reduced for one to two weeks following surgery.⁵ Postoperative complications may include swelling, bruising and limited mouth opening along with difficulty with eating, which can be a major concern to patients and has not been appreciated by healthcare professionals in the past.⁶ However, patients are often most concerned about postoperative pain, which may be severe. Approximately one in two patients will experience pain despite analgesic therapy, even one week after surgery.5 The pain experienced after oral surgery is a validated and widely used pain model for the clinical evaluation of analgesic efficacy.7

Paracetamol (acetaminophen) and ibuprofen are commonly prescribed analgesics used extensively in the management of postoperative third molar pain.^{8,9} In 2010, a novel drug marketed as Nuromol was introduced in the UK,¹⁰ this single tablet includes both paracetamol and ibuprofen. Early trials have shown encouraging data on its analgesic efficacy,¹⁰⁻¹² and we were keen to include this new drug in our meta-analyses. Recent systematic reviews^{13,14} have looked at the efficacy and safety of ibuprofen and paracetamol individually, without direct comparison, for postoperative pain management. These reviews have included the findings of studies involving a wide variety of types of surgery such as inguinal hernia surgery, caesarean section, orthopaedic surgery and the removal of wisdom teeth. Only one review to date looks at paracetamol specifically in relation to postoperative third molar removal pain,¹⁵ although two other reviews of single dose postoperative analgesics include subgroup analyses for dental pain only.13,16 There is some debate as to whether dental pain is different from other pain. It has been suggested that the effect of certain analgesics including tramadol is worse for dental pain than for other types of postsurgical pain.17

OBJECTIVES

In this review we investigated the optimal dose of ibuprofen *versus* paracetamol by direct comparison, taking into account the side effects of different doses of the drugs. This would inform dentists, oral surgeons and their patients of the optimal strategy for best pain relief when considering ibuprofen or paracetamol (or a combination of both) following the surgical removal of wisdom teeth.

PRACTICE

Table 1 A summary of the doses used in the included studies

	Daniels 2009	Forbes 1990	Hersch 2000*	Mehlisch 1995	Mehlisch 2010	Mehlisch 2010a	Olson 2001*
Paracetamol 500 mg						Х	
Paracetamol 600 mg		Х					
Paracetamol 1,000 mg	Х		Х	Х	Х	Х	Х
lbuprofen 200 mg		Х				Х	
lbuprofen 400 mg	Х	Х	Х	Х	Х	Х	Х
lbuprofen 512 mg	Х						
Paracetamol 250 mg/ Ibuprofen 100 mg						Х	
Paracetamol 500 mg/ Ibuprofen 200 mg					Х	Х	
Paracetamol 1,000 mg/ Ibuprofen 400 mg					Х	Х	
*liquigel formula							

Table 2 Five domains for risk of bias

Bias	Criteria for low risk of bias in included studies
Random sequence generation (selection bias)	Method of randomisation must be clearly stated
Allocation concealment (selection bias)	Method for blinding all parties involved in the study must be detailed
Incomplete outcome data (attrition bias)	All primary outcome measures must be reported on as detailed in the method
Selective reporting (reporting bias)	All drop outs and missing data must be accounted for, adverse events must be included in the analysis
Other bias	Method of anaesthetic given is clearly defined and unlikely to be a cause of bias in the trail

DESIGN

This review was completed according to the *Cochrane handbook for systematic reviews of interventions*.¹⁸ More information on the work of the Oral Health Group is available online.¹⁹

SUBJECTS AND METHODS

All included studies were randomised controlled double-blinded clinical trials. Crossover studies were included provided there was a wash out period of at least 14 days.

Participants

Patients of all health states without intolerances/ allergies to the study drugs who required the surgical removal of a lower wisdom tooth or teeth that required bone removal or at least registering a baseline pain intensity of moderate to severe pain. Patients who required removal of an additional tooth or teeth were also included. Surgery was undertaken under local anaesthesia, intravenous sedation or general anaesthesia. Patients taking concurrent analgesia were excluded.

Interventions

Ibuprofen, paracetamol or a combination of both given as a single dose postoperatively by mouth in any dose and in any formulation (for example, immediate or slow release).

Searching

We searched the following electronic databases:

- The Cochrane Oral Health Group's Trials Register (to 20 May 2013)
- The Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochane Library 2013, Issue 4)
- MEDLINE (1946 to 20 May 2013)
- EMBASE (1980 to 20 May 2013)
- MetaRegister of Controlled Trials (www.controlledtrials.com) (to 20 May 2013).

Two review authors independently and in duplicate scanned the titles and abstracts (when available) of all reports identified. Data was extracted using specially designed data extraction forms. Any disagreement was discussed and a third review author consulted where necessary. Authors were contacted for clarification of missing information. Data were excluded until further clarification was available if agreement was not reached.



Fig. 1 Risk of bias summary: review authors' judgements about each risk of bias item for each included study. Key: red = high risk of bias; yellow = unclear risk of bias; green = low risk of bias

OUTCOME MEASURES

Pain relief

Authors commonly report on the results of analgesic trials using mean data with associated standard deviations, this is a problem as the data may be asymmetrically distributed and if used in meta-analyses will lead to potentially erroneous conclusions.²⁰ It is therefore important to derive dichotomous data from the continuous data presented in trials before using the data in meta-analyses. The team at the Oxford Pain Relief Unit and Nuffield Department of Anaesthetics have derived a method for dichotomising this data; the detailed background and verification were published over three papers in the late 1990s.²⁰⁻²² From the data presented in the trials, the proportion of patients achieving 50% pain relief (50% maximum total pain relief [TOTPAR])) was calculated and used in the meta-analysis. Other Cochrane reviews have made use of these measures in their analyses.13-15 Summed pain intensity difference (SPID) essentially measures the same outcome as TOTPAR. If data were unavailable to calculate TOTPAR, SPID would have been calculated. If data on both TOTPAR and SPID were available, TOTPAR was chosen in preference. Outcomes were assessed for 2 hours and 6 hours post-dosing (where possible). For these dichotomous outcomes, the estimate of an intervention was expressed as risk ratios together with 95% confidence intervals.

Table 3 Comparison of ibuprofer	n versus parace	etamol				
Patient or population: patients with p Settings: Intervention: Ibuprofen 400			h			
	Illustrative comparative risks* (95% Cl)			No. of participants (studies)	Quality of the evidence (GRADE)	
Outcomes	Assumed ¹ risk Corresponding risk		Relative effect (95% Cl)			Comments
	Control	Ibuprofen versus paracetamol		()		
Proportion of patient with > 50% max pain relief (TOTPAR) over 6 hours – Ibuprofen 400 mg versus paracetamol 1,000 mg categorical scale follow-up: 6 hours	Study population		RR 1.47 (1.28 to 1.69)			
	49 per 100 72 per 100 (62 to 82)			646 (5 studies)		
	Moderate			040 (3 Studies)	⊕⊕⊕⊕ high	
	56 per 100 83 per 100 (72 to 95)					
Proportion of patient with >50% max) over 2 hours - 55 per 100 71 per 100 (60 to 85)					
pain relief (TOTPAR) over 2 hours -						
lbuprofen 400 mg versus paracetamol 1,000 mg categorical scale follow-up:	Moderate		nn 1.30 (1.09 (0 1.55)	645 (5 Studies)	⊕⊕⊕⊕ high	
2 hours	62 per 100 81 per 100 (68 to 97)					

"The basis for the assumed risk (for example, the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: confidence interval; RR: risk ratio; OR: odds ratio. GRADE Working Group grades of evidence – High quality: further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: further research is very likely to have an important impact on our confidence in the estimate of effect and bot the estimate.

This is the median control group risk based on paracetamol being the control group.

Use of rescue medication

Data on the percentage of patients taking rescue medication over the study period were also included in a separate meta-analysis.

RESULTS

Seven studies were included in this review.^{10,11,23-27} They contained data on 2,241 participants. All of these studies included a direct comparison of ibuprofen to paracetamol or the combination of both agents in the same drug. The majority of the trials (six) were conducted in the USA, with one trial conducted in Puerto Rico.²⁷ Four of the trials were completed in clinical research facilities, ^{10,11,23,26} two in university dental hospitals^{25,27} and one in a private oral surgery clinic.²⁴

Characteristics of the participants

The participants were broadly similar in the included trials; all contained the following exclusion criteria:

- History of significant disease
- Ongoing painful conditions (other than the third molar[s] scheduled for removal)
- Allergy/intolerance to the study drugs
- Patients currently taking long-term analgesics
- Malabsorption states (not mentioned in Mehlisch 1995²⁶)
- Gastrointestinal complaints (not mentioned in Mehlisch 1995²⁶)
- Psychotic illness or drug abuse (not mentioned in Mehlisch 1995²⁶)
- Concomitant medication that would interfere with the study drugs (not

mentioned in Forbes 1990²⁴)

- Pregnancy and/or breastfeeding (not mentioned in Mehlisch 1995²⁶)
- Migraine (not mentioned in Forbes 1990,²⁴ Hersh 2000²⁵ or Olson 2001²⁷).

Age ranges were broadly similar with 16-40 years accounting for the vast majority of participants.

Characteristics of the interventions

See Table 1 for a summary of the doses used in the included studies.

Type of anaesthetic used

In two studies, general anaesthetic with supplemental local anaesthetic was used.^{24,26} Local anaesthetic alone was used in one study.²⁷ Local anaesthetic with supplemental sedation was used in four studies, one using inhalation sedation with nitrous oxides,²³ two with nitrous oxide, diazepam and a barbituate,^{10,11} and in one study 'most patients' received intravenous conscious sedation.²⁵

Number of doses of analgesic given

For the purposes of data extraction in this review, only the data from the first postoperative dose were used. The patients were monitored for between 6 and 8 hours from this first dose before re-medication.

Risk of bias in included studies

Risk of bias was assessed using the five domains as described in Table 2. Figure 1 provides a summary of the risk of bias judgement in the included studies. 'A bias is a systematic error, or deviation from the truth, in results or inferences'.¹⁸ Bias in clinical trials can lead to underestimation or overestimation of the true effect of an intervention.

Comparison one: ibuprofen versus paracetamol

The most relevant comparison was between ibuprofen given as a 400 mg dose and paracetamol given as a 1,000 mg dose as these are the most commonly prescribed doses in clinical practice.

Outcome TOTPAR – greater than 50% pain relief over 6 hours

The overall risk ratio was 1.47 (95% CI 1.28 to 1.69; p <0.00001), indicating that 47% more patients achieved at least 50% of the maximum pain relief over 6 hours in the ibuprofen group.

Outcome TOTPAR – greater than 50% pain relief over 2 hours

The overall risk ratio was 1.30 (95% CI 1.09 to 1.55; p <0.00001), indicating that 30% more patients achieved at least 50% of the maximum pain relief over 2 hours in the ibuprofen group compared to the paracetamol group.

See Table 3 for analysis of this comparison.

Comparison two: combined (ibuprofen and paracetamol) versus single drugs

The two outcomes for TOTPAR were only based on data from one trial,¹⁰ therefore they

PRACTICE

Patient or population: patients wi Settings: Intervention: Combined							
	Illustrative con	nparative risks* (95% CI)					
Outcomer	Assumed ¹ risk Corresponding risk		Relative effect (95% Cl)	No. of participants	Quality of the	Comments	
Outcomes	Control Combined (ibuprofen and paracetamol) versus single drugs			(studies)	evidence (GRADE)	comments	
Proportion of patient with	Study populati	on					
>50% max pain relief (TOTPAR) over 6 hours – paracetamol 1,000 mg/ibuprofen 400 mg <i>versus</i> paracetamol 1,000 mg & ibuprofen 400 mg categorical scale follow-up: 6 hours	38 per 100 67 per 100 (50 to 90)		RR 1.77 (1.32 to 2.39)				
	Moderate			170 (1 study)	$\oplus \oplus \oplus \ominus$ moderate ¹		
	38 per 100 67 per 100 (50 to 91)		-				
proportion of patient with >	Study populati	on					
50% max pain relief (TOTPAR) over 2 hours – paracetamol 1,000mg/ibuprofen 400 mg versus paracetamol 1,000 mg and ibuprofen 400 mg categorical scale follow-up: 2 hours	37 per 100 48 per 100 (34 to 68)						
	Moderate		RR 1.29 (0.91 to 1.85)	170 (1 study)	$\oplus \oplus \oplus \ominus$ moderate ¹		
	37 per 100	48 per 100 (34 to 68)					

Quality of evidence downgraded due to serious imprecision.

	Combined Drug		Individua	Individual Drugs Events Total		Risk Ratio			Risk Ratio		
Study or Subgroup	Events	Events Total				M-H, Fixed, 95% C	I	M-H, Fixed		o Cl	
2.5.1 Paracetamol 1000	Omg/Ibruprofe	n 400mg versu	s Paracetamol 100	00mg and lb	oruprofen 400	ng					
Mehlisch 2010	21	67	71	103	26.5%	0.45 (0.31, 0.66)		-	-		
Mehlisch 2010a	42	149	72	148	34.3%	0.58 (0.43, 0.79)					
Subtotal (95% CI)		216		251	60.8%	0.52 (0.41, 0.67)			•		
Total events	63		143								
Heterogeneity: Chi ² = 0. Test for overall effect: 2.5.2 Paracetamol 500	Z = 5.33 (P < 0	0.00001)	Paragetamol 500	ma and Ibru	profen 200ma						
	31	143		ng and toru 151	39.2%			-			
Mehlisch 2010	31	143	85	151	39.2%	0.39 (0.27, 0.54)					
Subtotal (95% CI)		143		151	39.2%	0.39 (0.21, 0.54)		•			
Total events	31		85								
Heterogeneity: not appl Test for overall effect: Z		00001)									
Total (95% Cl)		359		402	100.0%	0.47 (0.39, 0.57)		•			
Total events	94		228								
Heterogeneity: $Chi^2 = 3$.	14, df = 2 (P = = 7.60 (P < 0.0		ò				0.01	0.1	0.01	10	100

cannot be considered as meta-analyses. All of the comparisons were between paracetamol 1,000 mg and ibuprofen 400 mg in the same tablet, and the same constituent drugs given as single tablets. It was not possible to derive TOTPAR and/or SPID data as the trial¹¹ used a two-stage design; despite contact with the authors, we did not obtain the specific data required to dichotomise the trial results for meta-analysis.

Outcome TOTPAR – greater than 50% pain relief over 6 hours

This comparison demonstrates a risk ratio

of 1.77 (95% CI 1.32 to 2.39; p = 0.0002), indicating that 77% more patients achieved at least 50% of the maximum pain relief over 6 hours in the combined drug group as did in the single drug group.

Outcome TOTPAR – greater than 50% pain relief over 2 hours

This outcome demonstrates a risk ratio of 1.29 (95% CI 0.91 to 1.85; p = 0.15), indicating that 29% more patients achieved at least 50% of the maximum pain relief over 2 hours in the combined drug group as did in the single drug group.

Number of patients using rescue medication at 8 hours

The results of two studies were included in this analysis,^{10,11} which compared the efficacy of a combination of paracetamol 1,000 mg/500 mg with ibuprofen 400 mg/200 mg in the same pill with the individual constituent drugs taken together. The lower dose was included here in order to perform a meta-analysis of single *vs* combined drugs. There was no difference between the subgroups (p = 0.39), and the overall risk ratio was 1.67 (95% CI 1.48 to 1.90; p <0.00001) indicating that 67% fewer patients used rescue medication over

the first 6 hours in the combined drug group compared to the individual constituent drug group at this dose.

See Table 4 and Figure 2 for further details.

Summary of findings

Using the software GRADE profiler 3.6, the quality of the body of evidence was assessed for both comparisons: ibuprofen versus paracetamol, and combined (ibuprofen and paracetamol) versus single drugs. TOTPAR and use of rescue medication were assessed as SPID is measuring the same outcome as TOTPAR. A summary of findings for the two comparisons is shown in Table 3 and Table 4. These tables show that all of the outcomes for comparing ibuprofen versus paracetamol were found to be of quality. The comparisons for combined (ibuprofen and paracetamol) versus single drugs for TOTPAR are both of moderate quality as they were downgraded due to being based on data from single studies and the imprecision of estimate. The evidence for use of rescue medication was assessed as high quality.

CONCLUSIONS

There is high quality evidence that ibuprofen is superior to paracetamol at doses of 400 mg ibuprofen and 1,000 mg paracetamol; these are the most frequently used doses in clinical practice. This review proves ibuprofen to be superior to paracetamol in terms of analgesic efficacy when used postoperatively for pain management following the surgical removal of lower wisdom teeth. It is important to be aware that the data in this review only relate to single dose postoperative usage of the trial drugs. The combined drugs containing both agents show promising outcomes, with metaanalysis of the use of rescue medication at 8 hours providing high quality evidence that the combined drugs are superior to the single drugs. This finding is echoed by a recent Cochrane review that found that participants had a smaller chance of requiring rescue medication over 8 hours if they took the combined drug compared to the individual agents.²⁸ It has been suggested that these findings could be due to the formulation of the combined drug having a faster onset of analgesia.29 However, we found that at 2 hours postoperatively, there was no significant difference between the paracetamol, ibuprofen and combined drug, implying that

the drug had a 'delayed' effect relative to the single drug. That is, at 6 hours the combined drug was more effective. All drugs studied in this review are generally considered safe with minimal side effects noted when used for short-term pain relief. It is important to remember that many patients are able to tolerate paracetamol and ibuprofen, and on the basis of evidence in this review prescribing both analgesics either as individual tablets or in combination would take advantage of their differing pharmacological properties and achieve adequate pain relief for patients following the surgical removal of lower third molar teeth.

- Bailey E, Worthington H V, van Wijk A, Yates J M, Coulthard P, Afzal Z. Ibuprofen and/or paracetamol (acetaminophen) for pain relief after surgical removal of lower wisdom teeth. status and date: Cochrane Database Syst Rev 2013; 12: CD004624.
- McArdle L, Renton T. The effects of NICE guidelines on the management of third molar teeth. Br Dent J 2012; 213: E8-E8.
- Colorado-Bonnin M, Valmaseda-Castellon E, Berini-Aytes L, Gay-Escoda C. Quality of life following lower third molar removal. *Int J Oral Maxillofac Surg* 2006; 35: 343–347.
- Conrad S M, Blakey G H, Shugars D A, Marciani R D, Phillips C, White R P Jr. Patients' perception of recovery after third molar surgery. J Oral Maxillofac Surg 1999; 57: 1288–1294.
- Savin J, Ogden G R. Third molar surgery—a preliminary report on aspects affecting quality of life in the early postoperative period. Br J Oral Maxillofac Surg 1997; 35: 246–253.
- Ogden G, Bissias E, Ruta D, Ogston S. Quality of life following third molar removal: a patient versus professional perspective. Br Dent J 1998; 185: 407–410.
- Cooper S, Beaver W. A model to evaluate mild analgesics in oral surgery outpatients. *Clin Pharmacol Ther* 1976; 20: 241–250.
- Bailey E, Patel N, Coulthard P. Non-steroidal antiinflammatory drugs for pain after oral surgery. Oral Surgery 2014; epub ahead of print.
- Coulthard P, Bailey E, Patel N. Paracetamol (acetaminophen) for pain after oral surgery. Oral Surgery 2014; epub ahead of print.
- Mehlisch D R, Aspley S, Daniels S E, Bandy D P. Comparison of the analgesic efficacy of concurrent ibuprofen and paracetamol with ibuprofen or paracetamol alone in the management of moderate to severe acute postoperative dental pain in adolescents and adults: a randomized, double-blind, placebo-controlled, parallel-group, single-dose, two-centre, modified factorial study. *Clinical Ther* 2010; **32**: 882–895.
- Mehlisch D R, Aspley S, Daniels S E, Southerden K A, Christensen K S. A single-tablet fixed-dose combination of racaemic ibuprofen/paracetamol in the management of moderate to severe postoperative dental pain in adult and adolescent patients: a multicentre, two-stage, randomized, double-blind, parallel-group, placebo-controlled, factorial study. *Clinical Ther* 2010; **32**: 1033–1049.
- Mehlisch D R. The efficacy of combination analgesic therapy in relieving dental pain. JAm Dent Asoc 2002; 133: 861–871.

- Toms L, McQuay H J, Derry S, Moore R A. Single dose oral paracetamol (acetaminophen) for postoperative pain in adults. *Cochrane Database Syst Rev* 2008; 4: CD004602.
- Derry C, Derry S, Moore R A, McQuay H J. Single dose oral ibuprofen for acute postoperative pain in adults. *Cochrane Database Syst Rev* 2009; 3: CD001548.
- Weil K, Hooper L, Afzal Z et al. Paracetamol for pain relief after surgical removal of lower wisdom teeth. Cochrane Database Syst Rev 2007; 3: CD004487.
- Moore R A, Derry S, McQuay H J, Wiffen P J. Single dose oral analgesics for acute postoperative pain in adults. *Cochrane Database Syst Rev* 2011; 9: CD008659.
- Moore, R, McQuay H. Single-patient data metaanalysis of 3453 postoperative patients: oral tramadol versus placebo, codeine and combination analgesics. *Pain* 1997; 69: 287–294
- Higgins J P, Green S. Cochrane handbook for systematic reviews of interventions. Vol 4. Wiley, 2011.
- Cochrane Oral Health Group. Cochrane Oral Health Group. Online information available at http://ohg. cochrane.org/cochrane-oral-health-group (Accessed March 2014).
- Moore A, Moore O, McQuay H, Gavaghan D. Deriving dichotomous outcome measures from continuous data in randomised controlled trials of analgesics: use of pain intensity and visual analogue scales. *Pain* 1997; 69: 311–315.
- Moore A, McQuay H, Gavaghan D. Deriving dichotomous outcome measures from continuous data in randomised controlled trials of analgesics. *Pain* 1996; 66: 229–237.
- Moore A, McQuay H, Gavaghan D. Deriving dichotomous outcome measures from continuous data in randomised controlled trials of analgesics: verification from independent data. *Pain* 1997; 69: 127–130.
- Daniels S, Reader S, Berry P, Goulder M. Onset of analgesia with sodium ibuprofen, ibuprofen acid incorporating poloxamer and acetaminophen—a single-dose, double-blind, placebo-controlled study in patients with post-operative dental pain. Eur J Clin Pharmacol 2009; 65: 343–353.
- Forbes J A, Butterworth G A, Burchfield W H, Beaver W T. Evaluation of ketorolac, aspirin, and an acetaminophen-codeine combination in postoperative oral surgery pain. *Pharmacotherapy* 1990; **10:** 77S-93S.
- Hersh E V, Levin L M, Cooper S A *et al.* Ibuprofen liquigel for oral surgery pain. *Clin Ther* 2000; 22: 1306–1318.
- Mehlisch D R, Jasper R D, Brown P, orn S H, McCarroll K, Murakami A A. Comparative study of ibuprofen lysine and acetaminophen in patients with postoperative dental pain. *Clinical Ther* 1995; 17: 852–860.
- Olson N Z, Otero A M, Marrero I et al. Onset of analgesia for liquigel ibuprofen 400 mg, acetaminophen 1000 mg, ketoprofen 25 mg, and placebo in the treatment of postoperative dental pain. J Clin Pharmacol 2001; 41: 1238–1247.
- Derry C J, Moore R A, Derry S. Single dose oral ibuprofen plus paracetamol (acetaminophen) for acute postoperative pain. *Cochrane Database Syst Rev* 2013; 6: CD010210.
- Daniels S E, Goulder M A, Aspley S, Reader S. A randomised, five-parallel-group, placebo-controlled trial comparing the efficacy and tolerability of analgesic combinations including a novel singletablet combination of ibuprofen/paracetamol for postoperative dental pain. *Pain* 2011; **152:** 632–642.